Better Buy Right Now: Johnson & Johnson Vs. Pfizer
As large tech companies struggled this year, investors have had a chance to reevaluate their portfolios and identify where they may be underexposed to certain sectors.
One of those sectors may be healthcare, which is easy to understand. Because artificial intelligence (AI) has commanded the spotlight for the last several years and policy uncertainty swirls around that industry, it was easy for pharmaceutical stocks to slip under the radar.
That's why we'll look at two stocks that have climbed this year while the S 500 has slipped, to see if there's more momentum ahead. Those two are Johnson Johnson (NYSE: JNJ) and (NYSE: PFE).
Source Fool.com
Pfizer Inc. Aktie
23,55 €
1,77 %
Die Community zeigt bei Pfizer Inc. eine Tendenz zu Buy-Einschätzungen.
Eine Steigerung von über 20% ist für Pfizer Inc. möglich, angesichts eines Kursziels von 29 € gegenüber 23.55 €.
